ArticleTherapeutics and clinical risk management2025
OPRM1 A118G Polymorphism and Ondansetron Efficacy for Postoperative Nausea and Vomiting in Laparoscopic Gynaecological Surgery: A Retrospective Cohort Study.
Article in Therapeutics and clinical risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The OPRM1 A118G polymorphism has been implicated in modulating susceptibility to postoperative nausea and vomiting (PONV). Ondansetron, a 5-HT3 receptor antagonist, is widely utilized for PONV prophylaxis; however, whether its efficacy is influenced by OPRM1 A118G polymorphism remains unclear. Methods: We conducted a retrospective cohort study including patients undergoing laparoscopic gynecological surgery between January 2019 and December 2024; propensity score matching was used to adjust for confounders. OPRM1 A118G genotypes (AA, AG, GG) were analyzed through polymerase chain reaction and sequencing. PONV incidence and severity were assessed using the Visual Analog Scale (VAS) at various postoperative time points. Results: The Ondansetron group had significantly lower PONV incidence within 2 hours (38.82% vs 56.98%, Conclusion: The OPRM1 A118G polymorphism is associated with an increased risk of early PONV, particularly in patients with the G allele, which has been related to reduced μ-opioid receptor sensitivity and increased opioid requirements, thereby predisposing patients to a higher PONV risk. Ondansetron significantly reduces PONV incidence and severity, especially in patients with higher genetic susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.